SCHEMBL345688

SCHEMBL345688

CNC(=O)c1cc(COC(=O)NCCC2CCN(c3cncc(-c4ccc(F)cc4)n3)CC2)on1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
SCD O00767 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
DYRK1A Q13627 1/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
RBP4 P02753 1/20 0.35
CHRM4 P08173 2/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343963 0.90 MEN1 (0.37) FFAR4MEN1KMT2ACKS1BSKP1
SCHEMBL345341 0.87 CHRM4 (0.42) MEN1KMT2ACKS1BSKP1SKP2
SCHEMBL345267 0.86 NPC1 (0.43) MEN1KMT2ACHRM2POLBTHRB
SCHEMBL345088 0.82 PDE10A (0.44) MEN1KMT2ASCD
SCHEMBL345713 0.81 SCN9A (0.39) CKS1BSKP1SKP2CHRM4
SCHEMBL345619 0.81 TDP1 (0.38) FFAR4MEN1KMT2ACKS1BSKP1
SCHEMBL2325034 0.78 FFAR4 (0.50) FFAR4CKS1BSKP1SKP2CHRM2
SCHEMBL345122 0.78 CHRM4 (0.43) MEN1KMT2ACKS1BSKP1SKP2
SCHEMBL345285 0.77 CHRM4 (0.42) MEN1KMT2ACKS1BSKP1SKP2
SCHEMBL345825 0.76 HRH3 (0.39) SCDCHRM4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716289-B2 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-05-06 US disclosed
US-20120015950-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015950-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF INTS9, CDK8, SCN8A FFAR4 1409/4885MEN1 812/4885KMT2A 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.